Accel-Ondansetron ODT 4 & 8 mg: Data integrity concerns with product's bioequivalence data that could lead to incorrect dosing.
Is your product affected? Check the DIN and lot number on your package against the list in Health Canada's official notice.
See affected DINs and lot numbers on Health Canada ↗Why it was recalled
Product quality
What you should do
- Return the affected products to your local pharmacy for a replacement, and for proper disposal. If you are unsure whether your product is affected, check with your pharmacy.
- Consult a health care professional if you have used the affected product and you have health concerns.
- Report any health product-related side effects or complaints to Health Canada.
- Contact the companies if you have questions about their recall:Accel Pharma Inc., by contacting Betty Cory at Accel Quality Assurance by calling 416-271-4775, or by email at bcory@regxia.com
Other Recent Recalls
PDP-DIPHENHYDRAMINE
PDP-DIPHENHYDRAMINE 25 MG and 50 MG CAPSULES: Out-of-specification (Impurity)
Type II2026-11-09
Moderate health risk
Unauthorized injectable peptide and non-peptide drugs
Health Canada warns about contaminated unauthorized injectable peptides and non-peptide drugs
2026-11-06
ANTICOAGULANT SODIUM CITRATE SOLUTION, USP
ANTICOAGULANT SODIUM CITRATE SOLUTION, USP 4g/100mL and Potential Bag Leaks
2026-11-03
Recall data is sourced from Health Canada's Recalls and Safety Alerts open dataset. MedShort.ca is an independent tracking tool and does not provide medical advice — for questions about this recall, contact the manufacturer or your pharmacist, or read the full notice linked above.